# Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism

> **NCT03516773** · PHASE2 · COMPLETED · sponsor: **Entera Bio Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** EB612 (EBP05)
- **DRUG:** NATPARA/NATPAR

## Key facts

- **NCT ID:** NCT03516773
- **Lead sponsor:** Entera Bio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-17
- **Primary completion:** 2018-12-05
- **Final completion:** 2019-02-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516773, "Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03516773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*